Unfortunately, the encouraging results with single-agent BRAF inhibitors in melanoma, thyroid cancer, and lung cancer were not confirmed in previously treated BRAF V600E-mutant CRC. This evidence concerns the gene BRAF and thyroid gland carcinoma.